<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02383043</url>
  </required_header>
  <id_info>
    <org_study_id>R01DA033364-02</org_study_id>
    <nct_id>NCT02383043</nct_id>
  </id_info>
  <brief_title>Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer</brief_title>
  <official_title>Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua A. Lile, Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cocaine-use disorders continue to be a significant public health concern, yet no effective
      medications have been identified. The goal of this study is to establish a research platform
      for the development of medications for treatment of cocaine abuse and dependence. This study
      will incorporate choice self-administration procedures between drug and a non-drug
      alternative reinforcer presented during maintenance on d-amphetamine, which has been
      previously shown to reduce cocaine use.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2015</start_date>
  <completion_date type="Actual">April 5, 2018</completion_date>
  <primary_completion_date type="Actual">April 5, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative</measure>
    <time_frame>9 choice trials per cocaine dose level with each trial separated by 30 minutes</time_frame>
    <description>The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Lile et al., 2016) in which subjects made 9 choices between each available cocaine dose and money (US$6.00). Reinforcing effects are measured for each cocaine dose during both d-amphetamine and placebo maintenance.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Active Cocaine Users</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cocaine choice during d-amphetamine maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cocaine choice during placebo maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine</intervention_name>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_label>Placebo Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sustained Release d-Amphetamine</intervention_name>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <other_name>Dexedrine Spansule SR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recent cocaine use, otherwise healthy

        Exclusion Criteria:

          -  Laboratory results outside of clinically acceptable ranges, history of or current
             serious physical or psychiatric disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laboratory of Human Behavioral Pharmacology</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2015</study_first_posted>
  <results_first_submitted>January 30, 2019</results_first_submitted>
  <results_first_submitted_qc>March 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 11, 2019</results_first_posted>
  <last_update_submitted>March 17, 2019</last_update_submitted>
  <last_update_submitted_qc>March 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Joshua A. Lile, Ph.D.</investigator_full_name>
    <investigator_title>Joshua A. Lile, Ph.D., Associate Professor of Behavioral Science</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT02383043/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo, 30 mg d-Amphetamine, 60 mg d-Amphetamine</title>
          <description>Cocaine choice during placebo, 30 mg d-Amphetamine, 60 mg d-Amphetamine maintenance
Placebo and Cocaine
Placebo and Sustained Release d-Amphetamine</description>
        </group>
        <group group_id="P2">
          <title>30 mg d-Amphetamine, Placebo, 60 mg d-Amphetamine</title>
          <description>Cocaine choice during 30 mg d-Amphetamine, Placebo, 60 mg d-Amphetamine maintenance
Placebo and Cocaine
Placebo Sustained Release d-Amphetamine maintenance</description>
        </group>
        <group group_id="P3">
          <title>30 mg d-Amphetamine, 60 mg d-Amphetamine, Placebo</title>
          <description>Cocaine choice during 30 mg d-Amphetamine, 60 mg d-Amphetamine, Placebo maintenance
Placebo and Cocaine
Placebo and Sustained Release d-Amphetamine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo, 30 mg d-Amphetamine, 60 mg d-Amphetamine</title>
          <description>Cocaine choice during Placebo, 30 mg d-Amphetamine, 60 mg d-Amphetamine maintenance
Placebo and Cocaine
Placebo and Sustained Release d-Amphetamine</description>
        </group>
        <group group_id="B2">
          <title>30 mg d-Amphetamine, Placebo, 60 mg d-Amphetamine</title>
          <description>Cocaine choice during 30 mg d-Amphetamine, Placebo, 60 mg d-Amphetamine maintenance
Placebo and Cocaine
Placebo and Sustained Release d-Amphetamine</description>
        </group>
        <group group_id="B3">
          <title>30 mg d-Amphetamine, 60 mg d-Amphetamine, Placebo</title>
          <description>Cocaine choice during 30 mg d-Amphetamine, 60 mg d-Amphetamine, Placebo maintenance
Placebo and Cocaine
Placebo and Sustained Release d-Amphetamine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-Hispanic/Latino Black Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic/Latino White Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic/Latino Black Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic/Latino White Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Latino Black Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative</title>
        <description>The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Lile et al., 2016) in which subjects made 9 choices between each available cocaine dose and money (US$6.00). Reinforcing effects are measured for each cocaine dose during both d-amphetamine and placebo maintenance.</description>
        <time_frame>9 choice trials per cocaine dose level with each trial separated by 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>30 mg d-Amphetamine</title>
            <description>Cocaine choice during 30 mg d-amphetamine maintenance
Placebo and Cocaine
Sustained Release d-Amphetamine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>Cocaine choice during placebo maintenance
Placebo and Cocaine
Placebo</description>
          </group>
          <group group_id="O3">
            <title>60 mg d-Amphetamine</title>
            <description>Cocaine choice during 60 mg d-amphetamine maintenance
Placebo and Cocaine
Sustained Release d-Amphetamine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative</title>
          <description>The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Lile et al., 2016) in which subjects made 9 choices between each available cocaine dose and money (US$6.00). Reinforcing effects are measured for each cocaine dose during both d-amphetamine and placebo maintenance.</description>
          <units>cocaine choices</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo Cocaine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.06"/>
                    <measurement group_id="O2" value="0.94" spread="0.35"/>
                    <measurement group_id="O3" value="0.75" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mg/70 kg Cocaine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.43"/>
                    <measurement group_id="O2" value="2.50" spread="0.89"/>
                    <measurement group_id="O3" value="0.56" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 mg/70 kg Cocaine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.50"/>
                    <measurement group_id="O2" value="5.13" spread="0.93"/>
                    <measurement group_id="O3" value="1.50" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 mg/70kg Cocaine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" spread="0.89"/>
                    <measurement group_id="O2" value="6.00" spread="0.99"/>
                    <measurement group_id="O3" value="5.19" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>33 days per subject.</time_frame>
      <desc>Adverse event reporting consists of each the duration of each d-amphetamine maintenance condition as well as during the conduct of a medical safety session in which cocaine doses are administered prior to initiation of d-amphetamine maintenance.</desc>
      <group_list>
        <group group_id="E1">
          <title>Medical Safety Session</title>
          <description>Experimenter administered Placebo and Cocaine delivery. d-Amphetamine maintenance not yet initiated.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Cocaine choice during placebo d-Amphetamine maintenance
Placebo and Cocaine</description>
        </group>
        <group group_id="E3">
          <title>30 mg d-Amphetamine</title>
          <description>Cocaine choice during 30 mg d-Amphetamine maintenance
Placebo and Cocaine</description>
        </group>
        <group group_id="E4">
          <title>60 mg d-Amphetamine</title>
          <description>Cocaine choice during 60 mg d-Amphetamine maintenance
Placebo and Cocaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <description>Nausea and vomiting after smoking a cigarette following administration of cocaine doses during the medical safety session.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Chest pain after a session with placebo cocaine maintenance on 60 mg d-amphetamine. Cardiovascular monitoring revealed normal vital signs and heart rhythmicity. Pain determined to be musculoskeletal.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joshua A. Lile, Ph.D.</name_or_title>
      <organization>University of Kentucky</organization>
      <phone>859-420-0503</phone>
      <email>jalile2@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

